Cargando…

The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease

OBJECTIVE: Although low infliximab trough concentrations and antibodies to infliximab (ATI) are associated with poor outcomes in patients with Crohn's disease (CD), the clinical relevance of ATI in patients with adequate infliximab concentrations is uncertain. We evaluated this question using a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vande Casteele, Niels, Khanna, Reena, Levesque, Barrett G, Stitt, Larry, Zou, G Y, Singh, Sharat, Lockton, Steve, Hauenstein, Scott, Ohrmund, Linda, Greenberg, Gordon R, Rutgeerts, Paul J, Gils, Ann, Sandborn, William J, Vermeire, Séverine, Feagan, Brian G
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2015
Materias:	Inflammatory Bowel Disease
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4602247/ https://www.ncbi.nlm.nih.gov/pubmed/25336114 http://dx.doi.org/10.1136/gutjnl-2014-307883

Ejemplares similares

Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial
por: Cornillie, Freddy, et al.
Publicado: (2014)

A Pooled Analysis of Infections, Malignancy, and Mortality in Infliximab- and Immunomodulator-Treated Adult Patients With Inflammatory Bowel Disease
por: Lichtenstein, Gary R, et al.
Publicado: (2012)

A phase II study of laquinimod in Crohn's disease
por: D'Haens, Geert, et al.
Publicado: (2015)

The safety of vedolizumab for ulcerative colitis and Crohn's disease
por: Colombel, Jean-Frédéric, et al.
Publicado: (2017)

Top-down Infliximab Study in Kids with Crohn's disease (TISKids): an international multicentre randomised controlled trial
por: Cozijnsen, M A, et al.
Publicado: (2016)

Infliximab clearance decreases in the second and third trimesters of pregnancy in inflammatory bowel disease
por: Grišić, Ana‐Marija, et al.
Publicado: (2021)

How many biomarker measurements are needed to predict prognosis in Crohn's disease patients under infliximab?—A prospective study
por: Magro, Fernando, et al.
Publicado: (2023)

Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials
por: Panés, Julian, et al.
Publicado: (2017)

Serum trough levels of infliximab are not associated with peripheral arthralgia activity in patients with inflammatory bowel disease
por: Sekhri, Shaina, et al.
Publicado: (2021)

Adalimumab for the treatment of fistulas in patients with Crohn’s disease
por: Colombel, J-F, et al.
Publicado: (2009)

Population pharmacokinetics‐pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease
por: Rosario, M., et al.
Publicado: (2015)

Association between 6-thioguanine nucleotide levels and preventing production of antibodies to infliximab in patients with inflammatory bowel disease
por: Phillips, Jennifer, et al.
Publicado: (2023)

Multiple infliximab biosimilar switches appear to be safe and effective in a real‐world inflammatory bowel disease cohort
por: Gros, Beatriz, et al.
Publicado: (2023)

First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn’s disease: an open-label multicentre randomised controlled trial
por: Jongsma, Maria M E, et al.
Publicado: (2022)

Serious Infection and Mortality in Patients With Crohn's Disease: More Than 5 Years of Follow-Up in the TREAT™ Registry
por: Lichtenstein, Gary R, et al.
Publicado: (2012)

Impact on direct and indirect costs of switching patients with inflammatory bowel disease from intravenous to subcutaneous infliximab (CT-P13)
por: Carbery, Isabel, et al.
Publicado: (2023)

Cost-effectiveness of adalimumab, infliximab or vedolizumab as first-line biological therapy in moderate-to-severe ulcerative colitis
por: Yokomizo, Lauren, et al.
Publicado: (2016)

Tacrolimus or infliximab for severe ulcerative colitis: short-term and long-term data from a retrospective observational study
por: Minami, Naoki, et al.
Publicado: (2015)

A microbial signature for Crohn's disease
por: Pascal, Victoria, et al.
Publicado: (2017)

Development of the symptoms and impacts questionnaire for Crohn's disease and ulcerative colitis
por: Dulai, Parambir S., et al.
Publicado: (2020)

Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol
por: Hébuterne, Xavier, et al.
Publicado: (2013)

Adalimumab maintains remission of Crohn's disease after up to 4 years of treatment: data from CHARM and ADHERE
por: Panaccione, R, et al.
Publicado: (2013)

Distinct transcriptional signatures in purified circulating immune cells drive heterogeneity in disease location in IBD
por: Verstockt, Bram, et al.
Publicado: (2023)

Ustekinumab improves health‐related quality of life in patients with moderate‐to‐severe Crohn's disease: Results up to Week 104 of the STARDUST trial
por: Panés, Julian, et al.
Publicado: (2023)

Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn’s disease (ANDANTE I and II)
por: Danese, Silvio, et al.
Publicado: (2019)

Rapid Test for Infliximab Drug Concentration Allows Immediate Dose Adaptation
por: Van Stappen, Thomas, et al.
Publicado: (2016)

Infliximab: the evidence for its place in therapy in ulcerative colitis
por: Van Assche, Gert, et al.
Publicado: (2007)

Safety of Accelerated Infliximab Infusions in Children With Inflammatory Bowel Disease: A Retrospective Cohort Study
por: Jagt, Jasmijn Z., et al.
Publicado: (2023)

Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: 12 months results
por: Argüelles-Arias, Federico, et al.
Publicado: (2017)

SHIP deficiency causes Crohn's disease-like ileitis
por: Kerr, William G, et al.
Publicado: (2010)

Four-Year Maintenance Treatment With Adalimumab in Patients with Moderately to Severely Active Ulcerative Colitis: Data from ULTRA 1, 2, and 3
por: Colombel, Jean-Frederic, et al.
Publicado: (2014)

Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn’s disease: report of the OPERA study
por: Sandborn, William J, et al.
Publicado: (2018)

Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS)
por: Travis, Simon P L, et al.
Publicado: (2011)

Creeping fat formation and interaction with intestinal disease in Crohn's disease
por: Yin, Yi, et al.
Publicado: (2022)

Effects of vedolizumab on health‐related quality of life in patients with ulcerative colitis: results from the randomised GEMINI 1 trial
por: Feagan, B. G., et al.
Publicado: (2016)

Bacterial protein signals are associated with Crohn’s disease
por: Juste, Catherine, et al.
Publicado: (2014)

Treat‐to‐target and sequencing therapies in Crohn's disease
por: Garcia, Nicole M., et al.
Publicado: (2022)

A novel unconventional T cell population enriched in Crohn’s disease
por: Rosati, Elisa, et al.
Publicado: (2022)

Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health
por: Peyrin-Biroulet, Laurent, et al.
Publicado: (2011)

Developing a core outcome set for fistulising perianal Crohn’s disease
por: Sahnan, Kapil, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_1ifiqdq40vk3v37n4lk7ngi5v7